HKU announces new gene therapy Hepatitis B treatment
HKU's research team says all of its nine patients under the first stage of clinical trial have had their surface antigen levels reduced. Photo: RTHK
The University of Hong Kong's Faculty of Medicine said on Thursday that one of its 41 drugs under clinical trials for Hepatitis B may provide a cure for patients.
The new gene therapy consists of removing the Hepatitis B infected gene along the patient's genetic code to reduce the surface antigens of the virus and halt the integration of the virus with the human genome.
'If we can suppress the virus and also eradicate the virus, the patients will not suffer or have a minimal risk or lower risk of suffering from liver cancer development and cirrhosis or liver failure,' said Professor Yuen Man-fung, who heads the research team.
'And that obviously will bring hope and a better life for patients,' he added.
Currently, treatments for the disease can only help patients manage symptoms.
Patients are still at risk of developing liver cancer or other complications, despite being required to rely on lifelong medication to treat the disease.
The team said it has started testing the method on patients from March this year, and is hoping to enroll around 40 patients by the end of 2026.
It said all of its nine patients undergoing treatment have had their surface antigen levels reduced, but more research has to be done before more data can be finalised and revealed.
In Hong Kong, about six percent of the population live with the chronic disease.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RTHK
10 hours ago
- RTHK
'HK can play key role in burgeoning space economy'
'HK can play key role in burgeoning space economy' Professor Alfred Ho calls for collaboration among sectors in developing a space economy in Hong Kong. Photo: RTHK Hong Kong can foster collaboration between different sectors to develop a space economy locally, researchers said. That call came in a report, titled "Soaring into Space: Exploring the Industrial Opportunities of the New Space Economy for Hong Kong", which was jointly released by the Federation of Hong Kong Industries and City University. The dean of the university's college of liberal arts and social sciences, Alfred Ho, says Hong Kong's biggest advantages lie in its researchers at different universities that draw talent from the mainland and overseas and being a financial centre and having a good legal system. "I think Hong Kong can lead and also coordinate many forces and interests to participate in the new space economy," the professor said. For instance, the report suggests that Hong Kong fully leverage opportunities presented by the Hong Kong-Shenzhen Innovation and Technology Park to collaborate on resource and research developments. Ho added that since the space economy – which is still in its infancy and can involve the use of space technology by either governments or firms for such purposes as better satellite images for agricultural production – concerns industries from land development to even marine-related economic activities, Hong Kong can play the role of connecting all these sectors. He says institutions and companies are doing research right now individually, but that they need to work together in order to advance the space economy. "We are in a very initial stage, hopefully our report will kick-start some discussion." First released online in January, the report was updated as more places such as the Middle East and the European Union started to invest in the space economy.
HKFP
11 hours ago
- HKFP
Chikungunya fever poses ‘medium to high risk' of local transmission, warns Hong Kong health official
The mosquito-borne chikungunya fever poses a 'medium to high risk' of local transmission in Hong Kong, as thousands of cases were reported in the neighbouring Guangdong province, a city health official has warned. Albert Au, head of the Communicable Disease Branch of the Centre for Health Protection (CHP), said on an RTHK radio show on Thursday that Guangdong province had seen a 'localised outbreak' of chikungunya fever over the past few weeks following some imported cases. Based on the CHP's communication with Guangdong authorities, the southern Chinese province has logged around 6,100 cases so far, Au said. About 90 per cent of the cases were recorded in Foshan, but other cities such as Guangzhou, Zhongshan, and Dongguan have reported cases too, he added. While Hong Kong has not recorded any cases so far, authorities are 'on high alert,' Au said. 'It is a time for summer holidays, and Hongkongers love to travel to Guangdong province. With frequent travel, there is a high risk of imported cases,' the health official said. 'Hong Kong has more mosquitoes during summer,' he added. 'So if there are imported cases, there is a medium to high risk that it will lead to local transmission.' According to the CHP, chikungunya fever is most commonly transmitted to humans through the bites of infected female Aedes mosquitoes. While the vector Aedes aegypti is not found in Hong Kong, Aedes albopictus, another species that can also spread the disease, is commonly found in the city. Chikungunya fever causes rare fatalities, and its symptoms are milder than those of dengue fever, another mosquito-borne disease. However, chikungunya fever carries a higher transmission potential than dengue fever, Au said. Mosquito control measures Meanwhile, the Housing Department has stepped up measures to prevent and control mosquitoes in public housing estates in Hong Kong due to the chikungunya outbreak in Guangdong. According to a statement on Thursday, the department is conducting fogging operations to eliminate adult mosquitoes and has taken measures such as removing stagnant water and water-holding containers and keeping drains clear of blockages to prevent water accumulation.
RTHK
13 hours ago
- RTHK
Govt doubles subsidised drug list for chronic diseases
Govt doubles subsidised drug list for chronic diseases The Health Bureau says it's doubling the number of subsidised drugs under its chronic disease pilot scheme to cater to patients' demands. Photo: RTHK The government on Friday said it had almost doubled the number of drugs it subsidises under a pilot scheme, so that more medicines can be used by participating doctors to cater to patients' needs. The announcement came after the Health Bureau conducted a review to learn more about the demands of patients under the "Chronic Disease Co-care Pilot Scheme (CDCC Pilot Scheme)" that was launched almost two years ago. In a statement, the bureau said the coverage of its subsidised basic-tier drug list had been expanded from 59 to 114 items - starting on Friday. The drugs on the list are commonly used for treating chronic diseases such as diabetes, high blood pressure, and high blood cholesterol. Newly added drugs, meanwhile, include antidepressants, or medicines for managing chronic hepatitis B, osteoporosis, thyroid disorder, as well as medication to relieve asthma, gout, nausea, and dizziness. Under the scheme, patients prescribed with drugs on the list will not need to pay for such medication. And the drugs will form the "foundation" of the community drug formulary set to be launched in the future, which would be key in supporting the operation of the community pharmacy scheme. Launched in November 2023, as part of measures to improve Hong Kong's primary medical care, the pilot scheme provides subsidised screening services to residents aged 45 or above to detect if they have the so-called "three highs": high blood sugar, high blood pressure, and high blood cholesterol. Participating patients who are diagnosed with any of those conditions will receive subsidised treatment and medication. So far, some 140,000 participants have enrolled in the scheme, with over 85,000 of them already completing their screenings, and some 34,000 have been diagnosed with long-term diseases related to the "three highs".
